Analysis of pharmacogenomic screening data from Version 2 of the Genomics of Drug Sensitivity in Cancer (GDSC) CRC cell lines indicated that p53 wild-type CRC cell lines (n = 12) were significantly more sensitive to MLN4924 than p53 mutant models (n = 30; p = 0.019; Fig. 1a). This evidence concerns the gene TP53 and cancer.